Health

#2026/614Updated Payment Rates for Branded NHS Medicines

🇬🇧United Kingdom··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This regulation updates the payment percentages that certain manufacturers and suppliers of branded medicines must pay to the UK health authorities under the statutory scheme for branded health service medicines. From 1 July 2026, the payment rate for newer presentations is set at 16.5%, while older presentations are set at 11% for the rest of 2026 and 10.9% from 2027 onward. Pharmaceutical companies supplying branded medicines to the NHS should review pricing, rebate, and forecasting models before the new rates take effect.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Sets the newer presentation payment percentage at 16.5% from 1 July 2026.
  • Sets the older presentation payment percentage at 11% from 1 July 2026 to the end of 2026.
  • Reduces the older presentation payment percentage to 10.9% from 1 January 2027 onward.

Obligations

What this law requires

high

From 1 July 2026 to 31 December 2026, manufacturers and suppliers subject to the statutory scheme for branded health service medicines must calculate payments for newer presentations using a payment percentage of 16.5%.

manufacturers and suppliers of branded health service medicines subject to the statutory scheme
Applies from 1 July 2026 to the end of 2026
operational
high

From 1 July 2026 to 31 December 2026, manufacturers and suppliers subject to the statutory scheme for branded health service medicines must calculate payments for older presentations using a payment percentage of 11%.

manufacturers and suppliers of branded health service medicines subject to the statutory scheme
Applies from 1 July 2026 to the end of 2026
operational
high

From 1 January 2027 onward, manufacturers and suppliers subject to the statutory scheme for branded health service medicines must calculate payments for newer presentations using a payment percentage of 16.5%.

manufacturers and suppliers of branded health service medicines subject to the statutory scheme
Applies from 1 January 2027 and any subsequent calendar year
operational
high

From 1 January 2027 onward, manufacturers and suppliers subject to the statutory scheme for branded health service medicines must calculate payments for older presentations using a payment percentage of 10.9%.

manufacturers and suppliers of branded health service medicines subject to the statutory scheme
Applies from 1 January 2027 and any subsequent calendar year
operational
medium

For the period beginning 1 July 2026 and ending at the end of 2026, where amended regulation 3(1AB) applies, the applicable payment percentage is 8.7% rather than 16.5%.

manufacturers and suppliers of branded health service medicines subject to regulation 3(1AB) of the statutory scheme
Applies from 1 July 2026 to the end of 2026
operational

Affected Parties

Manufacturers of branded medicines supplied to the NHSSuppliers of branded medicines supplied to the NHS+1 more…

Tags

branded medicines,NHS,pharmaceutical pricing…